PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.52%
Positive EBIT growth while AGEN is negative. John Neff might see a substantial edge in operational management.
16.52%
Positive operating income growth while AGEN is negative. John Neff might view this as a competitive edge in operations.
16.61%
Positive net income growth while AGEN is negative. John Neff might see a big relative performance advantage.
17.14%
Positive EPS growth while AGEN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
17.14%
Positive diluted EPS growth while AGEN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend reduction while AGEN stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
9.84%
Positive OCF growth while AGEN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
13.18%
Positive FCF growth while AGEN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2671.03%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
90.48%
5Y OCF/share CAGR above 1.5x AGEN's 14.10%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
83.42%
3Y OCF/share CAGR above 1.5x AGEN's 45.80%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-2587.91%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
90.30%
5Y net income/share CAGR above 1.5x AGEN's 26.91%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
86.48%
3Y net income/share CAGR above 1.5x AGEN's 49.40%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1551.35%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-71.69%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-47.82%
Negative 3Y equity/share growth while AGEN is at 14.62%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.10%
Asset growth 1.25-1.5x AGEN's 9.51%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
15.36%
1.25-1.5x AGEN's 11.86%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-14.09%
We’re deleveraging while AGEN stands at 3.40%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-7.82%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-4.34%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.